Polarean Imaging Plc. operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The firm manufactures, sells, and services hyperpolarizes and ancillary equipment for biomedical imaging research. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. It also develops and manufactures MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. The company was founded on October 24, 2016 and is headquartered in London, the United Kingdom.